Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC.ALPN · Entity 90802 | Director | January 02, 2020 | January 07, 2020 |
| Apnimed, Inc.APMD · Entity 4910 | Director | July 30, 2026 | August 03, 2026 |
| Axcella Health Inc.AXLA · Entity 116059 | Director | May 19, 2022 | May 25, 2022 |
| Enumeral Biomedical Holdings, Inc.ENUM · Entity 179878 | Director | December 09, 2016 | December 13, 2016 |
| Longboard Pharmaceuticals, Inc.LBPH · Entity 85536 | Director | December 02, 2024 | December 03, 2024 |
| Tessera Defense & Homeland Security Inc.PHGE · Entity 8384 | Director | July 28, 2021 | July 30, 2021 |
| VEEVA SYSTEMS INCVEEV · Entity 2124 | Director | September 01, 2026 | September 03, 2026 |
| vTv Therapeutics Inc.VTVT · Entity 6614 | Director · Pres, CEO and Exec Chairperson | February 17, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALPINE IMMUNE SCIENCES, INC.
Report date January 02, 2020 · Filed January 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2030-01-01 | Direct | 7,650 |
Reported balance
After 2020-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-02 · Grant · Acquired 7,650 · Balance 7,650 F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2020 and 1/12th of the shares subject to the option shall vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F2: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2020 and 1/12th of the shares subject to the option shall vest monthly thereafter.
Apnimed, Inc.
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,500 |
Reported balance
After 2026-08-03 transaction · row 1
1 source rowRow 1 · 2026-08-03 · Purchase · Acquired 12,500 · Balance 12,500 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2036-05-28 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-03 · Disposition to issuer · Disposed 169,468 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2036-05-28 | Direct | 169,468 |
Reported balance
After 2026-08-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-03 · Grant · Acquired 169,468 · Balance 169,468 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 155,558 |
Reported balance
After 2026-07-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-30 · Grant · Acquired 155,558 · Balance 155,558 F2: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-03 · Disposition to issuer · Acquired 155,558 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 155,558 |
Reported balance
After 2026-08-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-03 · Grant · Acquired 155,558 · Balance 155,558 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 22,238 |
Reported balance
After 2026-07-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-30 · Grant · Acquired 22,238 · Balance 22,238 F3: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-03 · Disposition to issuer · Disposed 22,238 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 22,238 |
Reported balance
After 2026-08-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-03 · Grant · Acquired 22,238 · Balance 22,238 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.
F2: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F3: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Axcella Health Inc.
Report date May 19, 2022 · Filed May 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.70 · Expires 2032-05-18 | Direct | 40,000 |
Reported balance
After 2022-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-19 · Grant · Acquired 40,000 · Balance 40,000 F1: This option shall vest and become exercisable in twelve equal quarterly installments following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in twelve equal quarterly installments following the grant date.
Enumeral Biomedical Holdings, Inc.
Report date December 09, 2016 · Filed December 13, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 175,000 |
Reported balance
After 2016-12-09 transaction · row 1
1 source rowRow 1 · 2016-12-09 · Exercise / conversion · Acquired 175,000 · Balance 175,000 |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2019-07-30 | Direct | 43,750 |
Reported balance
After 2016-12-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-12-09 · Purchase · Acquired 43,750 · Balance 43,750 F2: The Reporting Person acquired the reported Warrants in a private sale transaction for cash consideration in the amount of $0.08 per warrant. F1: The Common Stock Purchase Warrants (the "Warrants") are exercisable immediately. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2016-12-09 | Direct | 175,000 |
Reported balance
After 2016-12-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-12-09 · Other · Acquired 175,000 · Balance 175,000 F3: Pursuant to an Offer to Amend and Exercise launched by the Issuer on October 28, 2016 (as subsequently amended, the "Offering"), the exercise price of each Warrant tendered in the Offering was reduced to $0.50 per Warrant, and participants in the Offering received four shares for each Warrant tendered rather than one share. Pursuant to the terms of the Offering, the expiration date of tendered Warrants was accelerated to December 9, 2016. The Reporting Person tendered all of the Warrants beneficially owned in the Offering. F1: The Common Stock Purchase Warrants (the "Warrants") are exercisable immediately. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2016-12-09 | Direct | 0 |
Reported balance
After 2016-12-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-12-09 · Exercise / conversion · Disposed 175,000 · Balance 0 F3: Pursuant to an Offer to Amend and Exercise launched by the Issuer on October 28, 2016 (as subsequently amended, the "Offering"), the exercise price of each Warrant tendered in the Offering was reduced to $0.50 per Warrant, and participants in the Offering received four shares for each Warrant tendered rather than one share. Pursuant to the terms of the Offering, the expiration date of tendered Warrants was accelerated to December 9, 2016. The Reporting Person tendered all of the Warrants beneficially owned in the Offering. F1: The Common Stock Purchase Warrants (the "Warrants") are exercisable immediately. |
Filing footnotes · ownership attribution and instrument terms
F1: The Common Stock Purchase Warrants (the "Warrants") are exercisable immediately.
F2: The Reporting Person acquired the reported Warrants in a private sale transaction for cash consideration in the amount of $0.08 per warrant.
F3: Pursuant to an Offer to Amend and Exercise launched by the Issuer on October 28, 2016 (as subsequently amended, the "Offering"), the exercise price of each Warrant tendered in the Offering was reduced to $0.50 per Warrant, and participants in the Offering received four shares for each Warrant tendered rather than one share. Pursuant to the terms of the Offering, the expiration date of tendered Warrants was accelerated to December 9, 2016. The Reporting Person tendered all of the Warrants beneficially owned in the Offering.
Longboard Pharmaceuticals, Inc.
Report date December 02, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2030-12-10 | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-12-02 · Disposition to issuer · Disposed 25,461 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2032-05-23 | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-02 · Disposition to issuer · Disposed 12,367 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.06 · Expires 2033-05-24 | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-12-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.94 · Expires 2034-05-22 | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-12-02 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").
F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Tessera Defense & Homeland Security Inc.
Report date July 28, 2021 · Filed July 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,500 |
Reported balance
After 2021-07-28 transaction · row 1
1 source rowRow 1 · 2021-07-28 · Purchase · Acquired 12,500 · Balance 12,500 F1: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I. |
| Common Stock WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2027-01-28 | Direct | 9,375 |
Reported balance
After 2021-07-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-28 · Purchase · Acquired 9,375 · Balance 9,375 F1: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I. F2: The common stock warrant will be exercisable six months after the date of issuance, at an exercise price of $5.00 per share and will expire five years from the date such warrant first becomes exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I.
F2: The common stock warrant will be exercisable six months after the date of issuance, at an exercise price of $5.00 per share and will expire five years from the date such warrant first becomes exercisable.
VEEVA SYSTEMS INC
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 15,651 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Exercise / conversion · Acquired 460 · Balance 15,651 F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,381 |
Reported balance
After 2026-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-01 · Exercise / conversion · Disposed 460 · Balance 1,381 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3: On June 17, 2026, the Reporting Person was granted 1,841 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2026, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer.
F3: On June 17, 2026, the Reporting Person was granted 1,841 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2026, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date.
vTv Therapeutics Inc.
Report date February 17, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $36.92 · Expires 2036-02-17 | Direct | 392,212 |
Reported balance
After 2026-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 140,000 · Balance 392,212 F1: The options vest 25% on the first anniversary of the grant date and in quarterly equal installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 25% on the first anniversary of the grant date and in quarterly equal installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 21:13 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 460 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-060522 · wk-form4_1788470011.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,381 Underlying: Class A Common Stock · 460 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 17, 2026, the Reporting Person was granted 1,841 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2026, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 17, 2026, the Reporting Person was granted 1,841 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2026, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:13 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 460 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-060522 · wk-form4_1788470011.xml · nonDerivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 22,238 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330507 · ownership.xml · derivative · entry 9 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,238 Underlying: Common Stock · 22,238 shares Expires 2036-07-29 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 22,238 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330507 · ownership.xml · derivative · entry 8 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 22,238 shares Expires 2036-07-29 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 155,558 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330507 · ownership.xml · derivative · entry 6 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,558 Underlying: Common Stock · 155,558 shares Expires 2036-07-29 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2 · derivative.exercise_date: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 155,558 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330507 · ownership.xml · derivative · entry 5 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 155,558 shares Expires 2036-07-29 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2 · derivative.exercise_date: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 169,468 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001193125-26-330507 · ownership.xml · derivative · entry 3 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,468 Underlying: Common Stock · 169,468 shares Expires 2036-05-28 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2 · derivative.exercise_date: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 169,468 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001193125-26-330507 · ownership.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 169,468 shares Expires 2036-05-28 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2 · derivative.exercise_date: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | PurchaseCommon Stock | 12,500 | $16.00 | $200,000.00 |
DisclosureSEC source: 0001193125-26-330507 · ownership.xml · nonDerivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 22,238 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330507 · ownership.xml · derivative · entry 7 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,238 Underlying: Class A Common Stock · 22,238 shares Expires 2036-07-29 F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 155,558 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330507 · ownership.xml · derivative · entry 4 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,558 Underlying: Class A Common Stock · 155,558 shares Expires 2036-07-29 F2 · derivative.exercise_date: One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:47 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | GrantRestricted Stock Units · Derivative | 1,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-044682 · wk-form4_1782161232.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,841 Underlying: Class A Common Stock · 1,841 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F2 · derivative.exercise_date: The RSUs were granted under the Issuer's Amended & Restated 2013 Equity Incentive Plan. The Reporting Person vests ownership in the RSUs over one year with 1/4 of the RSUs vesting on September 1, 2026, and 1/4 of the RSUs vesting on a quarterly basis thereafter, subject to continued service to the Issuer by the Reporting Person. F2 · derivative.expiration_date: The RSUs were granted under the Issuer's Amended & Restated 2013 Equity Incentive Plan. The Reporting Person vests ownership in the RSUs over one year with 1/4 of the RSUs vesting on September 1, 2026, and 1/4 of the RSUs vesting on a quarterly basis thereafter, subject to continued service to the Issuer by the Reporting Person. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:40 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 253 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040439 · wk-form4_1780519253.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 253 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 18, 2025, the Reporting Person was granted 1,013 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2025, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 18, 2025, the Reporting Person was granted 1,013 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2025, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:40 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 253 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040439 · wk-form4_1780519253.xml · nonDerivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:45 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 253 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-013950 · wk-form4_1772574319.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253 Underlying: Class A Common Stock · 253 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 18, 2025, the Reporting Person was granted 1,013 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2025, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 18, 2025, the Reporting Person was granted 1,013 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2025, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:45 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 253 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-013950 · wk-form4_1772574319.xml · nonDerivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:10 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantClass A Common Stock · Derivative | 140,000 | $36.92 Strike: $36.92 | $5,168,800.00 |
DisclosureSEC source: 0001264519-26-000002 · wk-form4_1771449023.xml · derivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director · Pres, CEO and Exec Chairperson 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 392,212 Underlying: Class A Common Stock ("Common Stock") · 140,000 shares Expires 2036-02-17 F1 · derivative.exercise_date: The options vest 25% on the first anniversary of the grant date and in quarterly equal installments thereafter. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 15:04 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | GiftClass A Common Stock | 2,491 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-054929 · wk-form4_1764774241.xml · nonDerivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,685 F2 · kind: This was a bona fide charitable gift with no payment in consideration. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 15:04 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 254 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-054929 · wk-form4_1764774241.xml · derivative · entry 3 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506 Underlying: Class A Common Stock · 254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F4 · derivative.exercise_date: On June 18, 2025, the Reporting Person was granted 1,013 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2025, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F4 · derivative.expiration_date: On June 18, 2025, the Reporting Person was granted 1,013 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2025, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 15:04 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 254 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-054929 · wk-form4_1764774241.xml · nonDerivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 23:04 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 253 | $0.00 | $0.00 |
DisclosureSEC source: 0001264519-25-000005 · wk-form4_1756940683.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 760 Underlying: Class A Common Stock · 253 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 18, 2025, the Reporting Person was granted 1,013 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2025, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 18, 2025, the Reporting Person was granted 1,013 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2025, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 23:04 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 253 | $0.00 | $0.00 |
DisclosureSEC source: 0001264519-25-000005 · wk-form4_1756940683.xml · nonDerivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:58 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | GrantRestricted Stock Units · Derivative | 1,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-032453 · wk-form4_1750453092.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,013 Underlying: Class A Common Stock · 1,013 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F2 · derivative.exercise_date: The RSUs were granted under the Issuer's Amended & Restated 2013 Equity Incentive Plan. The Reporting Person vests ownership in the RSUs over one year with 1/4 of the RSUs vesting on September 1, 2025, and 1/4 of the RSUs vesting on a quarterly basis thereafter, subject to continued service to the Issuer by the Reporting Person. F2 · derivative.expiration_date: The RSUs were granted under the Issuer's Amended & Restated 2013 Equity Incentive Plan. The Reporting Person vests ownership in the RSUs over one year with 1/4 of the RSUs vesting on September 1, 2025, and 1/4 of the RSUs vesting on a quarterly basis thereafter, subject to continued service to the Issuer by the Reporting Person. Read SEC document |
| June 01, 2025 Filed Jun 2, 2025 23:57 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-028906 · wk-form4_1748908626.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 19, 2024, the Reporting Person was granted 1,315 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 19, 2024, the Reporting Person was granted 1,315 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| June 01, 2025 Filed Jun 2, 2025 23:57 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-028906 · wk-form4_1748908626.xml · nonDerivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 00:10 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 328 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-009559 · wk-form4_1741046994.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329 Underlying: Class A Common Stock · 328 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 19, 2024, the Reporting Person was granted 1,315 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 19, 2024, the Reporting Person was granted 1,315 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 00:10 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 328 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-009559 · wk-form4_1741046994.xml · nonDerivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document |
| March 01, 2025 Filed Mar 7, 2025 21:20 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantEmployee stock option (right to buy) · Derivative | 108,000 | $19.66 Strike: $19.66 | $2,123,280.00 |
DisclosureSEC source: 0001641489-25-000007 · wk-form4_1741382420.xml · derivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director · Pres, CEO and Exec Chairperson 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,212 Underlying: Class A Common Stock · 108,000 shares Expires 2035-03-01 F1 · derivative.exercise_date: The options vest 25% on the first anniversary of the grant date and in quarterly equal installments thereafter. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:26 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 22,500 | Not disclosed Strike: $18.94 | Not disclosed |
DisclosureSEC source: 0001415889-24-028026 · form4-12032024_121218.xml · derivative · entry 4 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2034-05-22 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2 · price: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F2 · derivative.exercise_date: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:26 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $7.06 | Not disclosed |
DisclosureSEC source: 0001415889-24-028026 · form4-12032024_121218.xml · derivative · entry 3 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2033-05-24 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2 · price: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F2 · derivative.exercise_date: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:26 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 12,367 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001415889-24-028026 · form4-12032024_121218.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,367 shares Expires 2032-05-23 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2 · price: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F2 · derivative.exercise_date: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:26 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 25,461 | Not disclosed Strike: $3.62 | Not disclosed |
DisclosureSEC source: 0001415889-24-028026 · form4-12032024_121218.xml · derivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,461 shares Expires 2030-12-10 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2 · price: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F2 · derivative.exercise_date: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| December 01, 2024 Filed Dec 2, 2024 21:59 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-049600 · wk-form4_1733176778.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 657 Underlying: Class A Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 19, 2024, the Reporting Person was granted 1,315 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 19, 2024, the Reporting Person was granted 1,315 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| December 01, 2024 Filed Dec 2, 2024 21:59 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-049600 · wk-form4_1733176778.xml · nonDerivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 21:31 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | PurchaseClass A Common Stock | 1,844 | $16.96 | $31,268.52 |
DisclosureSEC source: 0001641489-24-000078 · wk-form4_1732051858.xml · nonDerivative · entry 3 SEKHRI PAUL J · CIK 0001264519 · Director · Pres, CEO and Exec Chairperson 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Sekhri on August 13, 2024. F4 · price: The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $16.70 to $17.00. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:31 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | PurchaseClass A Common Stock | 1,778 | $16.88 | $30,009.26 |
DisclosureSEC source: 0001641489-24-000078 · wk-form4_1732051858.xml · nonDerivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director · Pres, CEO and Exec Chairperson 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,156 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Sekhri on August 13, 2024. F3 · price: The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $16.71 to $17.00. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:31 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | PurchaseClass A Common Stock | 1,378 | $16.35 | $22,534.16 |
DisclosureSEC source: 0001641489-24-000078 · wk-form4_1732051858.xml · nonDerivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director · Pres, CEO and Exec Chairperson 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,378 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Sekhri on August 13, 2024. F2 · price: The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $15.65 to $16.50. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2024 Filed Sep 3, 2024 20:51 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-039144 · wk-form4_1725396680.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 986 Underlying: Class A Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 19, 2024, the Reporting Person was granted 1,315 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 19, 2024, the Reporting Person was granted 1,315 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| September 01, 2024 Filed Sep 3, 2024 20:51 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-039144 · wk-form4_1725396680.xml · nonDerivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document |
| June 19, 2024 Filed Jun 20, 2024 23:41 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | GrantRestricted Stock Units · Derivative | 1,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-029187 · wk-form4_1718926888.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,315 Underlying: Class A Common Stock · 1,315 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F2 · derivative.exercise_date: The RSUs were granted under the Issuer's Amended & Restated 2013 Equity Incentive Plan. The Reporting Person vests ownership in the RSUs over one year with 1/4 of the RSUs vesting on September 1, 2023, and 1/4 of the RSUs vesting on a quarterly basis thereafter, subject to continued service to the Issuer by the Reporting Person. F2 · derivative.expiration_date: The RSUs were granted under the Issuer's Amended & Restated 2013 Equity Incentive Plan. The Reporting Person vests ownership in the RSUs over one year with 1/4 of the RSUs vesting on September 1, 2023, and 1/4 of the RSUs vesting on a quarterly basis thereafter, subject to continued service to the Issuer by the Reporting Person. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 21:07 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-026404 · wk-form4_1717448824.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 21, 2023, the Reporting Person was granted 1,160 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2023, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 21, 2023, the Reporting Person was granted 1,160 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2023, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 21:07 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-026404 · wk-form4_1717448824.xml · nonDerivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:30 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $18.94 | $0.00 |
DisclosureSEC source: 0000950170-24-064644 · ownership.xml · derivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Voting common stock · 22,500 shares Expires 2034-05-22 F1 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 12 equal monthly installments commencing June 23, 2024, and in any event will become fully vested on the day before the Company's next annual meeting of stockholders. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 19:24 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008838 · wk-form4_1709666684.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290 Underlying: Class A Common Stock · 290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 21, 2023, the Reporting Person was granted 1,160 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2023, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 21, 2023, the Reporting Person was granted 1,160 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2023, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 19:24 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008838 · wk-form4_1709666684.xml · nonDerivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document |
| February 27, 2024 Filed Jun 13, 2024 20:40 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantEmployee stock option (right to buy) · Derivative | 89,212 | $11.81 Strike: $11.81 | $1,053,593.72 |
DisclosureSEC source: 0001641489-24-000040 · wk-form4_1718311197.xml · derivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,212 Underlying: Class A Common Stock · 89,212 shares Expires 2034-02-27 F1 · derivative.exercise_date: The options vests in equal quarterly installments over the three-year period beginning on February 27, 2024. The option was conditioned upon shareholder approval of the 2024 Equity Incentive Plan, which was approved by the shareholders on June 11, 2024. Read SEC document |
| December 01, 2023 Filed Dec 1, 2023 23:41 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-040495 · wk-form4_1701474062.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 580 Underlying: Class A Common Stock · 290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 21, 2023, the Reporting Person was granted 1,160 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2023, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 21, 2023, the Reporting Person was granted 1,160 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2023, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| December 01, 2023 Filed Dec 1, 2023 23:41 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-040495 · wk-form4_1701474062.xml · nonDerivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document |
| September 11, 2023 Filed Sep 13, 2023 00:06 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | SaleClass A Common Stock | 2,500 | $224.85 | $562,125.00 |
DisclosureSEC source: 0001628280-23-032128 · wk-form4_1694563589.xml · nonDerivative · entry 1 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,484 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 20, 2022. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 23:50 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-031447 · wk-form4_1693957830.xml · derivative · entry 2 SEKHRI PAUL J · CIK 0001264519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 870 Underlying: Class A Common Stock · 290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 21, 2023, the Reporting Person was granted 1,160 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2023, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 21, 2023, the Reporting Person was granted 1,160 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2023, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.